The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Andrew J. Wilson - JPMorgan Chase & Co, Research Division - Analyst
: I've got 3 questions, quite distinct, so I'll take them one at a time. I just wanted to ask around Flex-Tek. It's obviously been very good, particularly
second half performance. And momentum in those, particularly, I guess, the U.S. resi side is very good, and aerospace looks to be coming back.
Can you sort of give us sort of some help on what the outlook for FY '22 looks like, just conscious that those markets are seeing quite different
trends and are in sort of different phases versus previous peaks? Maybe if you could start there.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 28, 2021 / 7:30AM, SMIN.L - Full Year 2021 Smiths Group PLC Earnings Presentation
Question: Andrew J. Wilson - JPMorgan Chase & Co, Research Division - Analyst
: And then second one is just on Detection. I guess, clearly, a very different sort of trajectory to some of the other businesses with regard to order
supporting revenues, but then obviously, I guess, needing to win more orders on revenues, I guess, that have probably been pushed out by some
customers.
But kind of notwithstanding that backdrop, I'm interested in terms of the competitive dynamics, and you mentioned a number of contract wins in
the year. I guess, interested in terms of what you're seeing from competitors, if you feel this sort of [potent] market share, albeit that the market
necessarily isn't particularly helpful at the moment.
Question: Andrew J. Wilson - JPMorgan Chase & Co, Research Division - Analyst
: And maybe if I can ask, I guess, just a third one. And it's really just to clear up and, I guess, help me a little bit with your understanding. But there
was a separate release this morning in terms of talking about exercising the put option with regards to the Medical transaction. I know that there
were conditions seemingly associated with that. I mean it's probably a very simple broad question, but can you kind of clear up the implications
of that release and sort of what we need to take away from that?
|
